Satellos Bioscience Inc. Common Stock (MSLE) Stock Price

MSLEStock
$9.40+80.56%52W
Market Cap$199.43M
P/E
PEG Ratio
Div yield
Beta1.78

MSLE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-26.00%
Price vs S&P 500 (4W)-5.75%
VGM Score67.94

MSLE Earnings Surprise History

Q4 25-0.50est. -0.06
Q1 26-0.53est. -0.59
Q2 26-0.56est. -0.57

MSLE Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.22
4.20
4.27
4.27

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
MSLESatellos Bioscience Inc. Common Stock
B$9.40
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Satellos Bioscience Inc. Common Stock

Satellos Bioscience is a regenerative medicine company developing novel therapeutics to stimulate and restore muscle function in severe neuromuscular disorders. The company's lead program is an oral therapeutic for Duchenne muscular dystrophy that addresses dysregulation identified as a key driver of disease progression. Satellos' approach targets the root cause of muscle degeneration rather than symptomatic relief, positioning the therapy as a potential disease-modifying treatment.